Contributions
Abstract: 38
Type: Educational Session
Abstract Category: N/A
The key therapeutic challenge in multiple sclerosis remains the progression of neurological disability that occurs independently of relapse. Progressive MS can occur from clinical onset (primary progressive) or following a history of relapses (secondary progressive). Progressive MS can be further classified according to whether it occurs with or without clinical or radiological evidence of disease activity.
The therapeutic landscape in progressive MS is changing rapidly with the approval of ocrelizumab, a B-cell depleting anti-CD20 monoclonal antibody, for the treatment of primary progressive disease, and following the positive results of a registration trial of siponimod, a next generation selective S1P1/S1P5 sphingosine receptor modulator, in secondary progressive disease. Significant benefits have also been reported in trials of several other agents in progressive MS, including simvastatin, high dose biotin and ibudilast, and trials of additional therapies are currently ongoing. High dose biotin is also available in some countries on a named patient basis.
Given this rapidly evolving scenario, neurologists will now have to understand therapeutic selection and treatment monitoring in progressive forms of MS for the first time. Using informative clinical vignettes, this case-based course will review the current understanding of the basis of disability progression, how progressive MS can be treated, and how the therapeutic response can be measured. Data from recent successful clinical trials will be reviewed for insights into therapeutic selection based on patient characteristics, and the use of symptomatic treatments will also be highlighted. Lastly, clinically important unanswered questions and directions for future research will be outlined.
Disclosure: Prof Kapoor has received support from the UK National Institute of Health Research UCL/H Biomedical Research Centre and personal compensation for consultancies, lectures, participation in advisory boards, and/or support for travel to medical meetings from Actelion, Biogen, Genzyme, Novartis, Roche, Teva.
Bruce Cree has received personal compensation for consulting from Abbvie, Akili, Biogen, EMD Serono, GeNeuro and Novartis.
Abstract: 38
Type: Educational Session
Abstract Category: N/A
The key therapeutic challenge in multiple sclerosis remains the progression of neurological disability that occurs independently of relapse. Progressive MS can occur from clinical onset (primary progressive) or following a history of relapses (secondary progressive). Progressive MS can be further classified according to whether it occurs with or without clinical or radiological evidence of disease activity.
The therapeutic landscape in progressive MS is changing rapidly with the approval of ocrelizumab, a B-cell depleting anti-CD20 monoclonal antibody, for the treatment of primary progressive disease, and following the positive results of a registration trial of siponimod, a next generation selective S1P1/S1P5 sphingosine receptor modulator, in secondary progressive disease. Significant benefits have also been reported in trials of several other agents in progressive MS, including simvastatin, high dose biotin and ibudilast, and trials of additional therapies are currently ongoing. High dose biotin is also available in some countries on a named patient basis.
Given this rapidly evolving scenario, neurologists will now have to understand therapeutic selection and treatment monitoring in progressive forms of MS for the first time. Using informative clinical vignettes, this case-based course will review the current understanding of the basis of disability progression, how progressive MS can be treated, and how the therapeutic response can be measured. Data from recent successful clinical trials will be reviewed for insights into therapeutic selection based on patient characteristics, and the use of symptomatic treatments will also be highlighted. Lastly, clinically important unanswered questions and directions for future research will be outlined.
Disclosure: Prof Kapoor has received support from the UK National Institute of Health Research UCL/H Biomedical Research Centre and personal compensation for consultancies, lectures, participation in advisory boards, and/or support for travel to medical meetings from Actelion, Biogen, Genzyme, Novartis, Roche, Teva.
Bruce Cree has received personal compensation for consulting from Abbvie, Akili, Biogen, EMD Serono, GeNeuro and Novartis.